Consistent and significant real-world research is critical as GLP-1 drugs are a considerable driver of cost and utilization for our clients and employer groups. This data contributes to Primes holistic management approach to GLP-1 therapy, which was first showcased with its award-winning Year-1 persistence and cost-of-care data in 2023, Year-2 persistence data in July 2024 and Year-2 cost-of-care data in October 2024
And then when we look further down the road at some of what the pharma companies are doing, which is to come in with these other drugs that we talked about, kind of inferred about earlier on, which are these drugs that block this important hormone myostatin
Two people can lose the same amount of weight and end up in very different places
E66.01 Morbid (severe) obesity due to excess calories E66.09 Other obesity due to excess calories E66.1 Drug-induced obesity E66.2 Morbid obesity with alveolar hypoventilation E66.3 Overweight E66.8 Other obesity E66.9 Obesity, unspecified Note: When coding for obesity, its advisable to document the patients Body Mass Index (BMI) using the appropriate Z codes (Z68.- series) to provide a comprehensive clinical picture
visible for all concentrations)
If you exceed five days, skip the missed dose and administer it on your next scheduled day
